Genenta Science Announces Promising Follow-Up Data From Temferon Study, Stock Up In Pre-Market

(RTTNews) - Genenta Science S.p.A. (GNTA), Tuesday announced long-term follow-up data from its TEM-GBM study of Temferon in glioblastoma multiforme patients.

The study enrolled a total of 38 patients, with 25 patients receiving Temferon. Of this, two patients survived three years from the time of the first surgery.

The company noted that a 29 percent two-year survival rate for unmethylated MGMT patients, with median overall survival at 17 months. This is in comparison to patients receiving standard of care have shown a two-year survival rate of approximately 14 percent and a median overall survival of 13 to 15 months.

Also, the company has initiated the TEM-GU Phase 1 study, which intends to enroll 12 patients with genitourinary tumors, aiming to demonstrate the safety and tolerability of Temferon in patients with Metastatic Renal Cell Carcinoma by year-end.

In the pre-market hours, GNTA is moving up 11.99 percent, to $3.41 on the Nasdaq.